Literature DB >> 26593971

Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome.

Edmund C Jenkins1, Lingling Ye1, Sharon J Krinsky-McHale1, Warren B Zigman1, Nicole Schupf1,2, Wayne P Silverman3.   

Abstract

Previous studies have suggested that Alzheimer's disease (AD) causes an accelerated shortening of telomeres, the ends of chromosomes consisting of highly conserved TTAGGG repeats that, because of unidirectional 5'-3' DNA synthesis, lose end point material with each cell division. Our own previous work suggested that telomere length of T-lymphocytes might be a remarkably accurate biomarker for "mild cognitive impairment" in adults with Down syndrome (MCI-DS), a population at dramatically high risk for AD. To verify that the progression of cognitive and functional losses due to AD produced this observed telomere shortening, we have now examined sequential changes in telomere length in five individuals with Down syndrome (3F, 2M) as they transitioned from preclinical AD to MCI-DS (N = 4) or dementia (N = 1). As in our previous studies, we used PNA (peptide nucleic acid) probes for telomeres and the chromosome 2 centromere (as an "internal standard" expected to be unaffected by aging or dementia status), with samples from the same individuals now collected prior to and following development of MCI-DS or dementia. Consistent shortening of telomere length was observed over time. Further comparisons with our previous cross-sectional findings indicated that telomere lengths prior to clinical decline were similar to those of other adults with Down syndrome (DS) who have not experienced clinical decline while telomere lengths following transition to MCI-DS or dementia in the current study were comparable to those of other adults with DS who have developed MCI-DS or dementia. Taken together, findings indicate that telomere length has significant promise as a biomarker of clinical progression of AD for adults with DS, and further longitudinal studies of a larger sample of individuals with DS are clearly warranted to validate these findings and determine if and how factors affecting AD risk also influence these measures of telomere length.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Down syndrome; FISH with PNA (peptide nucleic acid) probes; biomarker; dementia status; mild cognitive impairment (MCI); telomere length in light intensity units; telomere length in microns; telomere longitudinal shortening

Mesh:

Substances:

Year:  2015        PMID: 26593971     DOI: 10.1002/ajmg.b.32389

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  4 in total

1.  Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort.

Authors:  Kelly N H Nudelman; Jue Lin; Kathleen A Lane; Kwangsik Nho; Sungeun Kim; Kelley M Faber; Shannon L Risacher; Tatiana M Foroud; Sujuan Gao; Justin W Davis; Michael W Weiner; Andrew J Saykin
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 2.  A Review of Biomarkers for Alzheimer's Disease in Down Syndrome.

Authors:  Ni-Chung Lee; Yin-Hsiu Chien; Wuh-Liang Hwu
Journal:  Neurol Ther       Date:  2017-07-21

3.  Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline.

Authors:  James H Cole; Tiina Annus; Liam R Wilson; Ridhaa Remtulla; Young T Hong; Tim D Fryer; Julio Acosta-Cabronero; Arturo Cardenas-Blanco; Robert Smith; David K Menon; Shahid H Zaman; Peter J Nestor; Anthony J Holland
Journal:  Neurobiol Aging       Date:  2017-04-18       Impact factor: 4.673

4.  Evidence for Accelerated Biological Aging in Young Adults with Prader-Willi Syndrome.

Authors:  Stephany H Donze; Veryan Codd; Layla Damen; Wesley J Goedegebuure; Matthew Denniff; Nilesh J Samani; Janiëlle A E M van der Velden; Anita C S Hokken-Koelega
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.